Continuum Advisory’s ARK Genomic Revolution ETF ARKG Stock Holding History

Continuum Advisory’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,837	Closed	-$79.7K	–	487
2025 Q1	$79.7K	Hold	3,837	–	–	0.01%	562
2024 Q4	$90.3K	Hold	3,837	–	–	0.01%	540
2024 Q3	$92.6K	Hold	3,837	–	–	0.01%	537
2024 Q2	$90.1K	Hold	3,837	–	–	0.01%	506
2024 Q1	$96.3K	Buy	+3,837	New	+$115K	0.01%	494
2022 Q1	–	Sell	-3,581	Closed	-$219K	–	377
2021 Q4	$219K	Sell	3,581 -84	-2%	-$5.81K	0.05%	278
2021 Q3	$274K	Hold	3,665	–	–	0.07%	234
2021 Q2	$339K	Sell	3,665 -312	-8%	-$26.5K	0.11%	199
2021 Q1	$359K	Buy	+3,977	New	+$394K	0.15%	124

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Continuum Advisory's ARKG Position: Q2 2025 in Review

Continuum Advisory sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2025, closing a stake of 3,837 shares — an estimated $79.7K sold.

Continuum Advisory first reported a position in ARKG in Q1 2021 and held it in 9 quarters. The position peaked at $359K in Q1 2021. 213 funds tracked by Wall St. Rank hold ARKG as of Q2 2025.

Continuum Advisory reported no remaining ARK Genomic Revolution ETF position as of Q2 2025 after selling out during the quarter.
Continuum Advisory sold 3,837 ARK Genomic Revolution ETF shares in Q2 2025, an estimated $79.7K.
Continuum Advisory first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 9 quarters.
Continuum Advisory's ARK Genomic Revolution ETF position peaked at $359K in Q1 2021.
213 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.